PRODIGY Final Report Supplementary Documents

CHEER checklist

	Item	Recommendation	Reported on
Section/Item	No		
Title and abstract			
Title	1	Identify the study as an economic evaluation or use more specific terms such as "cost-effectiveness analysis", and describe the interventions compared.	1
Abstract	2	Provide a structured summary of objectives, perspective, setting, methods (including study design and inputs), results (including base case and uncertainty analyses), and conclusions.	
Introduction			
Background and	3a	Provide an explicit statement of the broader context for the study.	15, 103
objectives Methods	3b	Present the study question and its relevance for health policy or practice decisions.	
Target population and subgroups	4	Describe characteristics of the base case population and subgroups analysed, including why they were chosen.	33, 103, 104
Setting and location	5	State relevant aspects of the system(s) in which the decision(s) need(s) to be made.	33, 103, 104
Study perspective	6	Describe the perspective of the study and relate this to the costs being evaluated.	104
Comparators	7	Describe the interventions or strategies being compared and state why they were chosen.	25, 103, 104

Time horizon	8	State the time horizon(s) over which costs and consequences are being evaluated and say	26, 31, 103,
		why appropriate.	104
Discount rate	9	Report the choice of discount rate(s) used for costs and outcomes and say why appropriate.	108
Choice of health	10	Describe what outcomes were used as the measure(s) of benefit in the evaluation and their	107, 108
outcomes		relevance for the type of analysis performed.	
Measurement of	11a	Single study-based estimates: Describe fully the design features of the single effectiveness	108
effectiveness		study and why the single study was a sufficient source of clinical effectiveness data.	
	11b	Synthesis-based estimates: Describe fully the methods used for identification of included	N/A
		studies and synthesis of clinical effectiveness data.	
Measurement and	12	If applicable, describe the population and methods used to elicit preferences for outcomes.	N/A
valuation of			
preference-based			
outcomes			
Estimating	13a	Single study-based economic evaluation: Describe approaches	104
resources and		used to estimate resource use associated with the alternative interventions. Describe primary	
costs		or secondary research methods for valuing each resource item in terms of its unit cost.	
		Describe any adjustments made to approximate to opportunity costs.	
	13b	Model-based economic evaluation: Describe approaches and data sources used to estimate	N/A
		resource use associated with model health states. Describe primary or secondary research	
		methods for valuing each resource item in terms of its unit cost. Describe any adjustments	
		made to approximate to opportunity costs.	

Currency, price	14	Report the dates of the estimated resource quantities and unit costs. Describe methods for	104
date, and	-	adjusting estimated unit costs to the year of reported costs if necessary. Describe methods for	-
conversion		converting costs into a common currency base and the exchange rate.	
Choice of model	15	Describe and give reasons for the specific type of decision analytical model used. Providing a	N/A
		figure to show model structure is strongly recommended.	
Assumptions	16	Describe all structural or other assumptions underpinning the decision-analytical model.	N/A
Analytical methods	17	Describe all analytical methods supporting the evaluation. This could include methods for	108
·		dealing with skewed, missing, or censored data; extrapolation methods; methods for pooling	
		data; approaches to validate or make adjustments (such as half cycle corrections) to a model;	
		and methods for handling population heterogeneity and uncertainty.	
Results			
Study parameters	18	Report the values, ranges, references, and, if used, probability distributions for all parameters.	N/A
		Report reasons or sources for distributions used to represent uncertainty where appropriate.	
		Providing a table to show the input values is strongly recommended.	
Incremental costs	19	For each intervention, report mean values for the main categories of estimated costs and	109, 113,
and outcomes		outcomes of interest, as well as mean differences between the comparator groups. If	105, 110,
		applicable, report incremental cost-effectiveness ratios.	111, 113, 114
Characterising	20a	Single study-based economic evaluation: Describe the effects of sampling uncertainty for the	108, 109,
uncertainty		estimated incremental cost and incremental effectiveness parameters, together with the	113, 114
		impact of methodological assumptions (such as discount rate, study perspective).	
	20b	Model-based economic evaluation: Describe the effects on the results of uncertainty for all	N/A
		input parameters, and uncertainty related to the structure of the model and assumptions.	

Characterising heterogeneity	21	If applicable, report differences in costs, outcomes, or cost-effectiveness that can be explained by variations between subgroups of patients with different baseline characteristics or other observed variability in effects that are not reducible by more information.	N/A
Discussion			
Study findings,	22	Summarise key study findings and describe how they support the conclusions reached.	Error!
limitations,		Discuss limitations and the generalisability of the findings and how the findings fit with current	Bookmark
generalisability,		knowledge.	not defined.
and current			
knowledge			
Other information			
Source of funding	23	Describe how the study was funded and the role of the funder in the identification, design, conduct, and reporting of the analysis. Describe other non-monetary sources of support.	130
Conflicts of interest	24	Describe any potential for conflict of interest of study contributors in accordance with journal policy. In the absence of a journal policy, we recommend authors comply with International Committee of Medical Journal Editors recommendations.	2